Andrew Walkty
- Molecular Medicine top 0.05%
- Antibiotic Resistance in Bacteria 76
-
- Antibiotic Use and Resistance 28
- Pharmacology top 0.2%
- Antibiotics Pharmacokinetics and Efficacy 42
- Clinical Biochemistry top 0.5%
- Bacterial Identification and Susceptibility Testing 35
- Endocrinology top 1%
-
- Antimicrobial Resistance in Staphylococcus 20
-
- Pneumonia and Respiratory Infections 17
- Urinary Tract Infections Management 16
-
- Streptococcal Infections and Treatments 10
Andrew Walkty
118 papers receiving 4.5k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Molecular Medicine 2.8k
- Applied Microbiology and Biotechnology 877
- Pharmacology 1.9k
- Clinical Biochemistry 652
- Endocrinology 468
Countries citing papers authored by Andrew Walkty
This map shows the geographic impact of Andrew Walkty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Walkty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Walkty more than expected).
Fields of papers citing papers by Andrew Walkty
This network shows the impact of papers produced by Andrew Walkty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Walkty. The network helps show where Andrew Walkty may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrew Walkty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 6 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 0 | |
| 6 | 2023 | 6 | |
| 7 | 2022 | 8 | |
| 8 | 2022 | 15 | |
| 9 | 2021 | 18 | |
| 10 | 2021 | 7 | |
| 11 | 2021 | 10 | |
| 12 | 2020 | 11 | |
| 13 | 2020 | 37 | |
| 14 | Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacillibreakdown → | 2019 | 311 |
| 15 | 2013 | 38 | |
| 16 | 2013 | 118 | |
| 17 | 2009 | 2 | |
| 18 | 2009 | 16 | |
| 19 | In Vitro Activity of Ceftobiprole Against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals | 2008 | 0 |
| 20 | 2002 | 286 |
About Andrew Walkty
Andrew Walkty is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology and Clinical Biochemistry, having authored 126 papers that have together received 4.7k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (76 papers), Antibiotics Pharmacokinetics and Efficacy (42 papers), Bacterial Identification and Susceptibility Testing (35 papers), Antibiotic Use and Resistance (28 papers), Antimicrobial Resistance in Staphylococcus (20 papers), Pneumonia and Respiratory Infections (17 papers), Urinary Tract Infections Management (16 papers) and Streptococcal Infections and Treatments (10 papers). The work is most often cited by research in Molecular Medicine (2.8k citations), Applied Microbiology and Biotechnology (877 citations) and Pharmacology (1.9k citations). Andrew Walkty has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include James A. Karlowsky, George G. Zhanel, Philippe Lagacé‐Wiens, Heather J. Adam, Daryl J. Hoban, Alfred S. Gin, Frank Schweizer, Sheryl Zelenitsky, Melanie Baxter and Joseph P. Lynch.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.